2013 Year in Review for OncoSec

2013 Year in Review for OncoSec

We’ve had a busy year at OncoSec. From our ongoing clinical trials to the formation of our melanoma board, research agreement with Old Dominion University and in between, the last year has moved us deeper into cancer research and engaging with patient communities. As we have only a matter of days left in 2013, we would like to look back at this year in review. Here is a selection of some of our activities this year:

Thought-Leaders to Steer Development of the Company’s ImmunoPulse Program

SAN DIEGO – February 26, 2013 — OncoSec Medical Inc. (OTCBB: ONCS), a company developing its advanced-stage ImmunoPulse DNA-based immunotherapy and NeoPulse therapy to treat solid tumor cancers, announced the formation of a Melanoma Advisory Board (MAB) for the company’s metastatic melanoma program.

Bringing together a group of distinguished industry experts in the melanoma and immunotherapy space, the MAB will provide insight and expertise into OncoSec’s clinical strategies for the development of the company’s ImmunoPulse program for the treatment of metastatic melanoma.

Punit Dhillon, President and CEO of OncoSec, stated, “We have assembled an impressive group of thought-leaders who have unparalleled experience developing pioneering intralesional therapies. Their expertise will be invaluable in establishing electroporation as a premier delivery mechanism for gene therapies and ImmunoPulse as a first-in-class commercial treatment of aggressive metastatic disease.”

Chaired by Dr. Adil I. Daud, the MAB is comprised of five individuals:

Dr. Sanjiv S. Agarwala
Sanjiv K. Agarwala, M.D. is Chief of Medical Oncology & Hematology and Director of the Melanoma and Immunology Program at St. Luke’s Cancer Center, Bethlehem, PA. He is Professor of Medicine at Temple University School of Medicine, Philadelphia, PA. He is nationally and internationally recognized as an expert in the research and treatment of melanoma.

Dr. Adil I. Daud
Adil I. Daud, M.D. is a professor of medicine at the University of California San Francisco and a nationally recognized expert in early phase drug development in skin cancer and solid tumors. Prior to joining UCSF Medical Center, he was Associate Professor and Director of the Affiliate Network at the Moffitt Cancer Center in Tampa, FL for seven years. Dr. Daud has won numerous awards, including the American Society for Clinical Oncology’s Young Investigator Award.

Dr. Axel Hauschild
Axel Hauschild, M.D., Ph.D. is professor and head of the Interdisciplinary Skin Cancer
Center at the Department of Dermatology, University Hospital Schleswig-Holstein in Kiel, Germany. From 2002 to 2010 he was the chairman of the Dermatologic Cooperative Oncology Group (DeCOG) in Germany. Dr. Hauschild is a board member of the European Association of Dermato-Oncology (EADO) and the co-chairman of the Global Melanoma Task Force
(GMTF).

Dr. Kim A. Margolin
Kim A. Margolin, M.D. is Professor of Medicine at the University of Washington in Seattle and a member of the Clinical Research Division at the Fred Hutchinson Cancer Research Center. Dr. Margolin served as chair of the Cancer Education Committee for ASCO in 2010 and has previously served on the Board of Directors of the Society for Immunotherapy of Cancer, the Medical Oncology Boards subcommittee of the ABIM (2002-2008), and the Oncologic Drugs Advisory Committee to the FDA (1994-2000).

Dr. Vernon K. Sondak
Vernon K. Sondak, M.D. is Chair of the Department of Cutaneous Oncology and Director of Surgical Education at the H. Lee Moffitt Cancer Center and Research Institute in Tampa, FL. He is also a Professor in the Departments of Oncologic Sciences and Surgery at the University of South Florida Morsani College of Medicine.


Real Time Web Analytics